Project Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of strokeand bleeding compared to…

Basic data

Title:
Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of strokeand bleeding compared to medical therapy: a prospective randomized clinical trial
Duration:
07/03/2018 to 31/12/2022
Abstract / short description:
Objectives: Study goal is to determine the clinical benefit of percutaneous catheter‐based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at high risk of stroke (CHA2DS2‐VASc Score ≥2) as well as high risk of bleeding as compared to best medical care (including a [non-vitamin K] oral anticoagulant [(N)OAC] when eligible).
Primary endpoint (net clinical benefit)
Survival time free of the composite of: - Stroke (including ischemic or hemorrhagic stroke) - Systemic embolism -Major bleeding (BARC type 3‐5) - Cardiovascular or unexplained death
Various secondary endpoints.
Keywords:
atrial fibrillation
Vorhofflimmern
LAA-closure
Vorhofohr-Verschluss
NOAC
Vitamin K Antagonist

Involved staff

Managers

Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Faculty of Medicine
University of Tübingen
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Internal Medicine Department III
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Funders

Help

will be deleted permanently. This cannot be undone.